BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34985720)

  • 21. Pathological and clinical features of cystic and noncystic glioblastomas.
    Utsuki S; Oka H; Suzuki S; Shimizu S; Tanizaki Y; Kondo K; Tanaka S; Kawano N; Fujii K
    Brain Tumor Pathol; 2006 Apr; 23(1):29-34. PubMed ID: 18095116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
    Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
    Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
    Saito T; Sugiyama K; Ikawa F; Yamasaki F; Ishifuro M; Takayasu T; Nosaka R; Nishibuchi I; Muragaki Y; Kawamata T; Kurisu K
    World Neurosurg; 2017 Jan; 97():21-26. PubMed ID: 27693246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pineal Region Glioblastomas: Clinical Characteristics, Treatment, and Survival Outcome.
    Niu X; Wang C; Zhou X; Yang Y; Liu Y; Zhang Y; Mao Q
    World Neurosurg; 2021 Feb; 146():e799-e810. PubMed ID: 33186787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
    Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
    Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insular glioblastoma: surgical challenges, survival outcomes and prognostic factors.
    Singh A; Das KK; Khatri D; Singh S; Gosal JS; Jaiswal S; Mishra P; Mehrotra A; Bhaisora K; Sardhara J; Srivastava AK; Jaiswal A; Behari S
    Br J Neurosurg; 2023 Feb; 37(1):26-34. PubMed ID: 33356607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
    Lee J; Ahn SS; Chang JH; Suh CO
    Yonsei Med J; 2018 Mar; 59(2):194-201. PubMed ID: 29436186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a Time Delay for Concomitant Chemoradiation After Surgery for Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup Analysis According to the Extent of Tumor Resection.
    Ahn S; Park JS; Song JH; Jeun SS; Hong YK
    World Neurosurg; 2020 Jan; 133():e640-e645. PubMed ID: 31568907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is age an additional factor in the treatment of elderly patients with glioblastoma? A new stratification model: an Italian Multicenter Study.
    Ius T; Somma T; Altieri R; Angileri FF; Barbagallo GM; Cappabianca P; Certo F; Cofano F; D'Elia A; Della Pepa GM; Esposito V; Fontanella MM; Germanò A; Garbossa D; Isola M; La Rocca G; Maiuri F; Olivi A; Panciani PP; Pignotti F; Skrap M; Spena G; Sabatino G
    Neurosurg Focus; 2020 Oct; 49(4):E13. PubMed ID: 33002864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    Wen J; Chen W; Zhu Y; Zhang P
    BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
    Li YM; Suki D; Hess K; Sawaya R
    J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.